RxDoctor Payments Data

Eveline Wu

Allergy · Chapel Hill, NCNPI 1770630584

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (57.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Pharming Healthcare, Inc. accounts for 92.8% of it on its own, with 8 other manufacturers making up the rest.

$136,161in general payments, 2019–2025

Across 154 payments — averaging $884.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pharming Healthcare, Inc.$126K
  • Sumitomo Pharma America, Inc.$8K
  • Astrazeneca UK Limited$2K
  • AstraZeneca$131
  • AbbVie$125
  • Sobi, Inc$123
  • plus $167 from 3 others
$942,239in research payments, 2019–2025

Across 30 payments — averaging $31,408 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • E.r. Squibb & Sons, L.L.C.$423K
  • Amgen$303K
  • Sumitomo Pharma America, Inc.$69K
  • Janssen Research & Development, LLC$46K
  • Pfizer$38K
  • AbbVie$31K
  • plus $33K from 3 others

What the payments were for

  • Consulting fees$78,25057%
  • Speaking & faculty fees$39,70529%
  • Travel & lodging$16,27012%
  • Food & beverage$1,9361%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few allergy providers in North Carolinato place this figure against a meaningful peer group, so we don't.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JoenjaLeniolisib Phosphate11$529,808

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharming Healthcare, Inc.Joenja$126,308$529,80811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy providers in North Carolinaon file to place this against a meaningful peer group, so we don't.

Other allergy in Chapel Hill

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →